Claims for Patent: 8,283,380

Summary for Patent: 8,283,380

Title:	Methods for treatment of parkinson's disease
Abstract:	New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s):	Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT)
Assignee:	Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:	10/559,982
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,283,380
Patent Claims:	1. In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of levodopa, the improvement comprising: concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day, while maintaining the patient on a stable dose of levodopa. 2. A method of treating idiopathic Parkinson's Disease, comprising: administering a therapeutically effective stable dose of levodopa; and concurrently administering safinamide, or a pharmaceutically acceptable salt thereof, on an oral dosage schedule of about 0.5 mg/kg/day to about 5 mg/kg/day. 3. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than about 5 mg/kg/day. 4. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered on a daily dosage schedule of no more than 200 mg/day. 5. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered for at least 12 weeks. 6. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered once daily. 7. The method of claim 1 or claim 2, wherein safinamide is administered as the methanesulfonate salt. 8. The method of claim 1 or claim 2, wherein levodopa is administered with a peripheral decarboxylase inhibitor selected from carbidopa and benserazide. 9. The method of claim 1 or claim 2, further comprising administering a catechol-O-methyltransferase inhibitor. 10. The method of claim 9, wherein said catechol-O-methyltransferase inhibitor is tolcapone or entacapone.